Valcyte® (valganciclovir) powder for oral solution

Pharmaceutical Product Information

In September 2022, Roche transferred the sponsorship and management of supply, customer support, medical information, regulatory services, sales and marketing of Valcyte 50 mg/mL powder for oral solution to Pharmaco (Australia) Ltd in Australia. The current Consumer Medicine Information (CMI) and Product Information (PI) for Valcyte are available from the Therapeutic Goods Administration (TGA) website at:

Roche Products Pty Limited ABN 70 000 132 865 | Roche Diagnostics Australia Pty Limited ABN 29 003 001 205 | Roche Diabetes Care Australia Pty Limited ABN 69 602 140 278. This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances. To report a suspected side effect or product complaint associated with the use of a Roche product, visitor contact Roche Patient Safety atRoche acknowledges the Traditional Owners of Country throughout Australia. We pay our respects to Elders past and present.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsDiagnostic solutionsRoche careersMediaPrivacy policyTerms of use